Category: Sponsors

Creso Pharma Market Update

Highlight Creso completes due diligence for Mernova Medicinal Inc.’s Canadian medicinal cannabis growing facility Construction contract signed, ground works commenced in Canada and project is on track for completion in Q3 2018 Canada amends the Cannabis Act. Bill C-45 to allow edible cannabis products in 2019; opportunities for Creso’s cannaQIX® and cannapeal® product ranges Over 200,000 patients now registered for medicinal cannabis in Canada Nova Scotia opens public consultation on medicinal cannabis Mernova Medicinal and Creso join 16 other licenced producers and Ad Standards group to further self-regulation for the industry Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) is pleased to provide this market update: Due diligence completed for medicinal cannabis growing facility Creso has successfully completed due diligence on the Mernova Medicinal Inc. acquisition, a 20,000 square foot medical cannabis growing facility in Nova Scotia, Canada. Also, the application for a medical cannabis cultivation licence under Health Canada’s Access to Cannabis for Medical Purposes Regulation (ACMPR) program is progressing. It will give Creso a significant competitive advantage as one of the few companies globally and the only medicinal cannabis company listed on the ASX with 100% ownership and capacity to cultivate, extract and manufacture its own innovative cannabis and hemp derived human and animal therapeutic products in Canada. These products will be for local distribution as well as export to countries which accept cannabis and hemp imports....

Read More

Liberty Leaf Receives $763,500 from Exercise of Warrants

by Todd | Oct 27, 2017 | Capital Markets, Investments and M&A | 0 comments VANCOUVER, Oct. 27, 2017 /CNW/ – Liberty Leaf Holdings Ltd. (CSE: LIB, OTCQB: LIBFF and FSE: HN3P) (the “Company” or “Liberty Leaf”) announced today it has received an aggregate $763,500 from the exercise of share purchase warrants. A total of 10,180,000 warrants were exercised at $0.075 and the Company issued a total of 10,180,000 common shares. The warrants were issued in connection with a non-brokered private placement financing in October 2015 and expired on October 26, 2017. Wil Rascan, CEO & President of Liberty Leaf commented: “We are very pleased with the level of support received from our shareholders as demonstrated by the recent exercise of warrants. With our significantly improved treasury, Liberty Leaf is wel positioned to further advance its corporate initiatives.” About Liberty Leaf Liberty Leaf Holdings Ltd. is a new Canadian-based, public company whose focus is to build and support a diversified portfolio of cannabis- sector businesses, including cultivation, value-added CBD/THC products, biotech research and supply chain products within this dynamic and fast-growing sector. Liberty Leaf also owns 100% of North Road Ventures, a late-stage applicant under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). On behalf of the Board Will Rascan, President & CEO Liberty Leaf Holdings Ltd. 700-838 W Hastings Street Vancouver, B.C. V6C 0A6 Telephone: (778)...

Read More

BCC Provides Update on Health Canada Licensed Producer Application and Owen Sound Facility Build Out

by Todd | Oct 26, 2017 | Capital Markets, Consulting | 0 comments TORONTO, Oct. 26, 2017 (GLOBE NEWSWIRE) — The Canadian Bioceutical Corporation (the “Company” or “BCC”) (CSE:BCC) (OTC:CBICF) today announced it has completed preparatory construction work and commenced detailed planning for the full build-out of its cannabis cultivation facility in Owen Sound, as well as provided an update on its application with Health Canada to obtain Licensed Producer status under the Access to Cannabis for Medical Purposes Regulation (“ACMPR”). On January 7, 2015 the Company announced that its subsidiary, BioCannabis Products Ltd., had filed a Marijuana for Medical Purposes Regulations application with Health Canada, and subsequently updated its application under the ACMPR.  On August 23, 2017 the Company was advised that its application was at the Detailed Review and Initiation of Security Clearance Process stage. Consequently, BCC has decided to commence further planning for the build out of its facility. Preparatory work on power and certain other utility systems has been completed, and the Company has now commenced more detailed design work for completion of the facility.  The Company anticipates being ready to commence cultivation in the latter half of 2018 for final inspection by Health Canada.  No assurances can be given at this point on the timeframe for inspection and potential subsequent granting of Licensed Producer status. “Commencing the full build-out of our Owen Sound facility is...

Read More

World Health Organization Explores International Rescheduling of CBD at Expert Committee Meeting

by Todd | Oct 26, 2017 | General, Medical Cannabis, Pharma & Biotech, Research | 0 comments October 26, 2017 Raul Elizalde to speak before WHO Expert Committee on Drug Dependence review of the psychoactivity of CBD. On November 6th, the World Health Organization’s (WHO) Thirty-Ninth meeting of the Expert Committee on Drug Dependence will begin a 5-day agenda set to determine the potential for harm or dependance of 16 different substances, including cannabidiol (CBD). Medical Marijuana, Inc. subsidiary HempMeds® will have a representative speaking before the committee on the first day regarding CBD. While WHO recognizes the medical use of certain substances is indispensable in the treatment of many conditions and that they should be available to patients for such purposes, the committee is also tasked with determining which substances should be regulated or banned internationally as scheduled drugs. WHO has a part in two of the United Nation’s central drug control conventions – the 1961 Single Convention on Narcotic Drugs and 1971 Convention on Psychotropic substances. WHO is responsible for conducting the medical, scientific, and public health evaluation of potentially harmful substances to determine the UN’s role in regulating them. This is done through the thirteen member Expert Committee on Drug Dependence (ECDD). The committee is made up of an international panel of experts in the field of drug addiction and abuse. The ECDD evaluates the dependence-producing...

Read More

Study: Retail Cannabis Sales Associated With Fewer Opioid Deaths

SHARE THIS POST Thursday, 19 October 2017 Fort Worth, TX: Retail cannabis distribution in Colorado is associated with a reduction in opioid-related mortality, according to data published online ahead of print in The American Journal of Public Health. A team of investigators from the University of North Texas School of Public Health, the University of Florida, and Emory University compared changes in the prevalence of monthly opioid-related deaths before and after Colorado retailers began selling cannabis to adults. Researchers compared Colorado’s data with trends in neighboring states (that had not implemented any change in marijuana’s legal status), and also sought to control for recent changes in the state’s prescription drug monitoring program. Authors reported a 6.5 percent decrease in monthly opioid deaths following retail cannabis sales. They wrote: “Colorado’s legalization of recreational cannabis sales and use resulted in a 0.7 deaths per month reduction in opioid-related deaths. This reduction represents a reversal of the upward trend in opioid-related deaths in Colorado.” Authors concluded, “Legalization of cannabis in Colorado was associated with short-term reductions in opioid-related deaths.” Their data is consistent with prior studies finding that cannabis access is associated with reductions in prescription drug spending, opioid-related hospitalizations, and opioid-related fatalities. For more information, contact Paul Armentano, NORML Deputy Director, at paul@norml.org. Full text of the study, “Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015,” appears in The American...

Read More